As shown in Table 4, 40 is highly potent against both wild-type ALK and all known ALK mutants including the gatekeeper L1196M mutant with excellent CNS penetration, which was approved in 2018 for the treatment of NSCLC [58]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.